semaglutide-话题@MedSci

#semaglutide#

14篇内容 | 1530人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2274102, encodeId=7b4722e410254, content=<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=2ad5104395dc' target=_blank style='color:#2F92EE;'>#糖尿病#</a></a> <a href='/topic/show?id=3ad9818917c' target=_blank style='color:#2F92EE;'>#肥胖#</a> <a href='/topic/show?id=ec01226163e' target=_blank style='color:#2F92EE;'>#中风#</a> <a href='/topic/show?id=8b7ae45899c' target=_blank style='color:#2F92EE;'>#神经退行性疾病#</a> <a href='/topic/show?id=db1c1612602' target=_blank style='color:#2F92EE;'>#semaglutide#</a> <a href='/topic/show?id=f5cd1e48099' target=_blank style='color:#2F92EE;'>#tirzepatide#</a>, objectTitle=JAMA Netw Open：糖尿病与肥胖患者中Semaglutide和Tirzepatide对神经退行性疾病及中风风险的影响, objectType=article, longId=887404, objectId=2c3b88e4046c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240711/1720691758183_92910.jpg, objectUrl=/article/show_article.do?id=2c3b88e4046c, replyNumber=0, likeNumber=16, createdTime=2025-07-20, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=2c3b88e4046c, moduleTitle=JAMA Netw Open：糖尿病与肥胖患者中Semaglutide和Tirzepatide对神经退行性疾病及中风风险的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c3b88e4046c)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2270822, encodeId=870e22e082248, content=<a href='/topic/show?id=db1c1612602' target=_blank style='color:#2F92EE;'>#semaglutide#</a> 近日，一项发表于《新英格兰医学杂志》的多中心、双盲、随机、安慰剂对照及活性药物对照的3期临床试验发布了Cagrilintide（长效人类胰淀素类似物）与Semaglutide（GLP-1受体激动剂）联合治疗超重或肥胖成人的最新研究成果。研究覆盖22个国家共3417名非糖尿病成人，治疗持续68周，结果显示两药联用在体重管理方面效果显著，相关心脏代谢指标和生活质量均有改善。, objectTitle=semaglutide, objectType=topic, longId=16126, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=3, createdTime=2025-06-25, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=浙江省, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2270803, encodeId=fd6522e080367, content=<a href='/topic/show?id=dc4b26688c5' target=_blank style='color:#2F92EE;'>#体重减轻#</a> <a href='/topic/show?id=db1c1612602' target=_blank style='color:#2F92EE;'>#semaglutide#</a> <a href='/topic/show?id=c6bb1069e0e8' target=_blank style='color:#2F92EE;'>#Cagrilintide#</a>, objectTitle=NEJM：Cagrilintide联用Semaglutide显著促进超重与肥胖成人的体重减轻——68周多中心随机对照临床试验结果解析, objectType=article, longId=883977, objectId=f89c8839e7b1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20231201/1701421016940_8096338.jpg, objectUrl=/article/show_article.do?id=f89c8839e7b1, replyNumber=0, likeNumber=20, createdTime=2025-06-25, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=f89c8839e7b1, moduleTitle=NEJM：Cagrilintide联用Semaglutide显著促进超重与肥胖成人的体重减轻——68周多中心随机对照临床试验结果解析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f89c8839e7b1)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2233061, encodeId=dd05223306173, content=<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a> <a href='/topic/show?id=db1c1612602' target=_blank style='color:#2F92EE;'>#semaglutide#</a> <a href='/topic/show?id=3cbe9e7892e' target=_blank style='color:#2F92EE;'>#阿尔茨海默病#</a>, objectTitle=Alzheimers Dement：一种流行的抗糖尿病和减肥药物有或可降低2型糖尿病患者罹患阿尔茨海默病的风险, objectType=article, longId=848438, objectId=585384843849, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/bioon-com/202401024/1729770460825_2185383.png, objectUrl=/article/show_article.do?id=585384843849, replyNumber=0, likeNumber=49, createdTime=2024-10-25, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1633179, encodeId=3e4716331e9b1, content=<a href='/topic/show?id=db1c1612602' target=_blank style='color:#2F92EE;'>#semaglutide#</a>, objectTitle=诺和诺德（Novo Nordisk）寻求欧盟批准Semaglutide治疗肥胖症, objectType=article, longId=204717, objectId=96c0204e17aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96c0204e17aa, replyNumber=0, likeNumber=92, createdTime=2021-06-01, rootId=0, userName=lfyang, userId=214a22029963, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96c0204e17aa, moduleTitle=诺和诺德（Novo Nordisk）寻求欧盟批准Semaglutide治疗肥胖症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96c0204e17aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1633178, encodeId=bcf916331e85a, content=<a href='/topic/show?id=db1c1612602' target=_blank style='color:#2F92EE;'>#semaglutide#</a>, objectTitle=诺和诺德的GLP-1激动剂索马鲁肽（Semaglutide）治疗肥胖症，III期临床试验成功, objectType=article, longId=194316, objectId=c1c619431626, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1c619431626, replyNumber=0, likeNumber=97, createdTime=2021-04-24, rootId=0, userName=lfyang, userId=214a22029963, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1c619431626, moduleTitle=诺和诺德的GLP-1激动剂索马鲁肽（Semaglutide）治疗肥胖症，III期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1c619431626)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1633177, encodeId=f2e316331e77a, content=<a href='/topic/show?id=db1c1612602' target=_blank style='color:#2F92EE;'>#semaglutide#</a>, objectTitle=诺和诺德的GLP-1激动剂semaglutide：非酒精性脂肪性肝炎的II期临床展现治疗潜力, objectType=article, longId=193810, objectId=97c7193810df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97c7193810df, replyNumber=0, likeNumber=78, createdTime=2020-10-14, rootId=0, userName=lfyang, userId=214a22029963, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97c7193810df, moduleTitle=诺和诺德的GLP-1激动剂semaglutide：非酒精性脂肪性肝炎的II期临床展现治疗潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97c7193810df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1633176, encodeId=37da16331e6ae, content=<a href='/topic/show?id=db1c1612602' target=_blank style='color:#2F92EE;'>#semaglutide#</a>, objectTitle=2019年ADA：口服semaglutide治疗2型糖尿病的心血管安全性可控, objectType=article, longId=168239, objectId=cddc168239ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cddc168239ad, replyNumber=0, likeNumber=76, createdTime=2019-12-09, rootId=0, userName=lfyang, userId=214a22029963, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cddc168239ad, moduleTitle=2019年ADA：口服semaglutide治疗2型糖尿病的心血管安全性可控, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cddc168239ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1633175, encodeId=f15416331e5ef, content=<a href='/topic/show?id=db1c1612602' target=_blank style='color:#2F92EE;'>#semaglutide#</a>, objectTitle=JAMA：Semaglutide在降糖及体重控制的效果优于西他列汀, objectType=article, longId=164496, objectId=43d31644961f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43d31644961f, replyNumber=0, likeNumber=84, createdTime=2019-12-18, rootId=0, userName=lfyang, userId=214a22029963, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43d31644961f, moduleTitle=JAMA：Semaglutide在降糖及体重控制的效果优于西他列汀, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43d31644961f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1633174, encodeId=883916331e4ab, content=<a href='/topic/show?id=db1c1612602' target=_blank style='color:#2F92EE;'>#semaglutide#</a>, objectTitle=Diabetologia：Semaglutide对2型糖尿病β细胞功能和血糖控制的影响, objectType=article, longId=106202, objectId=6cd310620285, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cd310620285, replyNumber=0, likeNumber=98, createdTime=2018-06-26, rootId=0, userName=lfyang, userId=214a22029963, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cd310620285, moduleTitle=Diabetologia：Semaglutide对2型糖尿病β细胞功能和血糖控制的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cd310620285)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1633173, encodeId=4a3e16331e3c9, content=<a href='/topic/show?id=db1c1612602' target=_blank style='color:#2F92EE;'>#semaglutide#</a>, objectTitle=Lancet Diabetes Endocrinol：Semaglutide 用于II型糖尿病临床新进展, objectType=article, longId=94701, objectId=dccc94e01c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dccc94e01c9, replyNumber=0, likeNumber=87, createdTime=2017-05-03, rootId=0, userName=lfyang, userId=214a22029963, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dccc94e01c9, moduleTitle=Lancet Diabetes Endocrinol：Semaglutide 用于II型糖尿病临床新进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dccc94e01c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1633172, encodeId=d70716331e2af, content=<a href='/topic/show?id=db1c1612602' target=_blank style='color:#2F92EE;'>#semaglutide#</a>, objectTitle=Lancet Diabetes Endocrinol：GLP类似物Semaglutide比甘精胰岛素疗法更具优势, objectType=article, longId=93206, objectId=92419320678, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92419320678, replyNumber=0, likeNumber=114, createdTime=2017-12-04, rootId=0, userName=lfyang, userId=214a22029963, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92419320678, moduleTitle=Lancet Diabetes Endocrinol：GLP类似物Semaglutide比甘精胰岛素疗法更具优势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92419320678)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1633170, encodeId=be7e16331e050, content=<a href='/topic/show?id=db1c1612602' target=_blank style='color:#2F92EE;'>#semaglutide#</a>, objectTitle=EASD 2016：诺和诺德长效GLP-1降糖药semaglutide三大功效：降糖，减肥，降低心血管风险, objectType=article, longId=78310, objectId=11a0e8310ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11a0e8310ab, replyNumber=0, likeNumber=83, createdTime=2017-05-20, rootId=0, userName=lfyang, userId=214a22029963, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11a0e8310ab, moduleTitle=EASD 2016：诺和诺德长效GLP-1降糖药semaglutide三大功效：降糖，减肥，降低心血管风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11a0e8310ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1633168, encodeId=e9a5163316808, content=<a href='/topic/show?id=db1c1612602' target=_blank style='color:#2F92EE;'>#semaglutide#</a>, objectTitle=ADA 2016：诺和诺德第二款兼具降糖及减肥的降糖药semaglutide（索马鲁肽）III期临床疗效显著, objectType=article, longId=71033, objectId=e336e1033ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e336e1033ae, replyNumber=0, likeNumber=113, createdTime=2017-05-26, rootId=0, userName=lfyang, userId=214a22029963, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e336e1033ae, moduleTitle=ADA 2016：诺和诺德第二款兼具降糖及减肥的降糖药semaglutide（索马鲁肽）III期临床疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e336e1033ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1633171, encodeId=ea3416331e16d, content=<a href='/topic/show?id=db1c1612602' target=_blank style='color:#2F92EE;'>#semaglutide#</a>, objectTitle=EASD 2016：诺和诺德semaglutide使高危2型糖尿病患者主要心血管事件风险显著降低26%, objectType=article, longId=78355, objectId=803ae8355cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=803ae8355cc, replyNumber=0, likeNumber=80, createdTime=2017-02-16, rootId=0, userName=lfyang, userId=214a22029963, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=803ae8355cc, moduleTitle=EASD 2016：诺和诺德semaglutide使高危2型糖尿病患者主要心血管事件风险显著降低26%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=803ae8355cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1633167, encodeId=2a1b163316eaa, content=<a href='/topic/show?id=db1c1612602' target=_blank style='color:#2F92EE;'>#semaglutide#</a>, objectTitle=长效GLP-1降糖药semaglutide显著降低2型糖尿病患者重大心血管事件风险（SUSTAIN 6研究）, objectType=article, longId=67351, objectId=ce4c6e35197, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce4c6e35197, replyNumber=0, likeNumber=92, createdTime=2016-10-07, rootId=0, userName=lfyang, userId=214a22029963, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce4c6e35197, moduleTitle=长效GLP-1降糖药semaglutide显著降低2型糖尿病患者重大心血管事件风险（SUSTAIN 6研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce4c6e35197)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1633169, encodeId=897b163316945, content=<a href='/topic/show?id=db1c1612602' target=_blank style='color:#2F92EE;'>#semaglutide#</a>, objectTitle=NEJM：Semaglutide不会威胁2型糖尿病患者的心血管安全性, objectType=article, longId=77711, objectId=71f1e771115, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71f1e771115, replyNumber=0, likeNumber=66, createdTime=2017-03-12, rootId=0, userName=lfyang, userId=214a22029963, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71f1e771115, moduleTitle=NEJM：Semaglutide不会威胁2型糖尿病患者的心血管安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=71f1e771115)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

semaglutide

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#糖尿病# #肥胖# #中风# #神经退行性疾病# #semaglutide# #tirzepatide#

JAMA Netw Open：糖尿病与肥胖患者中Semaglutide和Tirzepatide对神经退行性疾病及中风风险的影响

2025-07-20发表于上海

yangchou (审核中...)

前往app查看评论内容

全文收起 #semaglutide# 近日，一项发表于《新英格兰医学杂志》的多中心、双盲、随机、安慰剂对照及活性药物对照的3期临床试验发布了Cagrilintide（长效人类胰淀素类似物）与Semaglutide（GLP-1受体激动剂）联合治疗超重或肥胖成人的最新研究成果。研究覆盖22个国家共3417名非糖尿病成人，治疗持续68周，结果显示两药联用在体重管理方面效果显著，相关心脏代谢指标和生活质量均有改善。

2025-06-25发表于浙江省

梅斯管理员 (审核中...)

前往app查看评论内容

#体重减轻# #semaglutide# #Cagrilintide#

NEJM：Cagrilintide联用Semaglutide显著促进超重与肥胖成人的体重减轻——68周多中心随机对照临床试验结果解析

2025-06-25发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#索马鲁肽# #semaglutide# #阿尔茨海默病#

2024-10-25发表于上海

lfyang (审核中...)

前往app查看评论内容

#semaglutide#

诺和诺德（Novo Nordisk）寻求欧盟批准Semaglutide治疗肥胖症

2021-06-01

lfyang (审核中...)

前往app查看评论内容

#semaglutide#

诺和诺德的GLP-1激动剂索马鲁肽（Semaglutide）治疗肥胖症，III期临床试验成功

2021-04-24

lfyang (审核中...)

前往app查看评论内容

#semaglutide#

诺和诺德的GLP-1激动剂semaglutide：非酒精性脂肪性肝炎的II期临床展现治疗潜力

2020-10-14

lfyang (审核中...)

前往app查看评论内容

#semaglutide#

2019年ADA：口服semaglutide治疗2型糖尿病的心血管安全性可控

2019-12-09

lfyang (审核中...)

前往app查看评论内容

#semaglutide#

JAMA：Semaglutide在降糖及体重控制的效果优于西他列汀

2019-12-18

lfyang (审核中...)

前往app查看评论内容

#semaglutide#

Diabetologia：Semaglutide对2型糖尿病β细胞功能和血糖控制的影响

2018-06-26

lfyang (审核中...)

前往app查看评论内容

#semaglutide#

Lancet Diabetes Endocrinol：Semaglutide 用于II型糖尿病临床新进展

2017-05-03

lfyang (审核中...)

前往app查看评论内容

#semaglutide#

Lancet Diabetes Endocrinol：GLP类似物Semaglutide比甘精胰岛素疗法更具优势

2017-12-04

lfyang (审核中...)

前往app查看评论内容

#semaglutide#

EASD 2016：诺和诺德长效GLP-1降糖药semaglutide三大功效：降糖，减肥，降低心血管风险

2017-05-20

lfyang (审核中...)

前往app查看评论内容

#semaglutide#

ADA 2016：诺和诺德第二款兼具降糖及减肥的降糖药semaglutide（索马鲁肽）III期临床疗效显著

2017-05-26

lfyang (审核中...)

前往app查看评论内容

#semaglutide#

EASD 2016：诺和诺德semaglutide使高危2型糖尿病患者主要心血管事件风险显著降低26%

2017-02-16

lfyang (审核中...)

前往app查看评论内容

#semaglutide#

长效GLP-1降糖药semaglutide显著降低2型糖尿病患者重大心血管事件风险（SUSTAIN 6研究）

2016-10-07

lfyang (审核中...)

前往app查看评论内容

#semaglutide#

NEJM：Semaglutide不会威胁2型糖尿病患者的心血管安全性

2017-03-12

科室
- - 订阅+
  - 更多科室
工具
服务